Abstract
Antimicrobial agents in the macrolide family have long been considered drugs of potential utility in the management of infections caused by Streptococcus pneumoniae. However, with the emergence of macrolide resistance, the clinical value of macrolides in pneumococcal infections is threatened. In part, as a consequence of the development of macrolide resistance, recently the first agent in the ketolide antimicrobial class, telithromycin, was developed and introduced into clinical practice. The ketolides are macrolide antimicrobials whose chemistry has been modified so as avoid the effects of the most common mechanisms of macrolide resistance with S pneumoniae. This discussion reviews the current state of resistance to macrolides and ketolides with S pneumoniae in North America.
TY - JOUR
T1 - Macrolide and ketolide resistance with Streptococcus pneumoniae.
A1 - Doern,Gary V,
PY - 2006/11/23/pubmed
PY - 2007/1/16/medline
PY - 2006/11/23/entrez
SP - 1109
EP - 24
JF - The Medical clinics of North America
JO - Med Clin North Am
VL - 90
IS - 6
N2 - Antimicrobial agents in the macrolide family have long been considered drugs of potential utility in the management of infections caused by Streptococcus pneumoniae. However, with the emergence of macrolide resistance, the clinical value of macrolides in pneumococcal infections is threatened. In part, as a consequence of the development of macrolide resistance, recently the first agent in the ketolide antimicrobial class, telithromycin, was developed and introduced into clinical practice. The ketolides are macrolide antimicrobials whose chemistry has been modified so as avoid the effects of the most common mechanisms of macrolide resistance with S pneumoniae. This discussion reviews the current state of resistance to macrolides and ketolides with S pneumoniae in North America.
SN - 0025-7125
UR - https://www.unboundmedicine.com/medline/citation/17116439/Macrolide_and_ketolide_resistance_with_Streptococcus_pneumoniae_
DB - PRIME
DP - Unbound Medicine
ER -